CUSIP: 75915K200
Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
60,661,369
-
Share change
-
+33,223,006
-
Total reported value
-
$18,074,000
-
Price per share
-
$0.30
-
Number of holders
-
36
-
Value change
-
+$9,813,926
-
Number of buys
-
18
-
Number of sells
-
7
Quarterly Holders Quick Answers
What is CUSIP 75915K200?
CUSIP 75915K200 identifies RGLS - REGULUS THERAPEUTICS INC - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2022
-
Previous quarter:
Q4 2021
Recent filing periods for CUSIP 75915K200:
Institutional Holders of REGULUS THERAPEUTICS INC - COM NEW (RGLS) as of Q1 2022
As of 31 Mar 2022,
REGULUS THERAPEUTICS INC - COM NEW (RGLS) was held by
36 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
60,661,369 shares.
The largest 10 holders included
FEDERATED HERMES, INC., NEA Management Company, LLC, DAFNA Capital Management LLC, VANGUARD GROUP INC, VICTORY CAPITAL MANAGEMENT INC, Sarissa Capital Management LP, Ikarian Capital, LLC, GEODE CAPITAL MANAGEMENT, LLC, PRICE T ROWE ASSOCIATES INC /MD/, and STATE STREET CORP.
This page lists
36
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.